Capricor Therapeutics (NASDAQ:CAPR) Price Target Raised to $15.00

Capricor Therapeutics (NASDAQ:CAPR) had its target price raised by Oppenheimer from $14.00 to $15.00 in a report released on Tuesday, Benzinga reports. They currently have an outperform rating on the biotechnology company’s stock.

Other analysts also recently issued reports about the company. Maxim Group restated a buy rating and set a $12.00 price objective on shares of Capricor Therapeutics in a report on Tuesday. HC Wainwright restated a buy rating and set a $40.00 price target on shares of Capricor Therapeutics in a research note on Tuesday. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and a consensus price target of $20.00.

Capricor Therapeutics Trading Down 2.5 %

Shares of CAPR opened at $4.99 on Tuesday. Capricor Therapeutics has a 12-month low of $2.68 and a 12-month high of $7.28. The stock has a market cap of $159.58 million, a P/E ratio of -5.74 and a beta of 3.92. The company has a 50-day moving average of $4.36 and a two-hundred day moving average of $5.18.

Capricor Therapeutics (NASDAQ:CAPR) last released its earnings results on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.03). The firm had revenue of $3.97 million during the quarter, compared to analysts’ expectations of $4.51 million. Capricor Therapeutics had a negative net margin of 102.93% and a negative return on equity of 220.27%. As a group, analysts forecast that Capricor Therapeutics will post -1.24 EPS for the current fiscal year.

Institutional Investors Weigh In On Capricor Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Jump Financial LLC bought a new stake in Capricor Therapeutics in the fourth quarter worth about $258,000. BNP Paribas Financial Markets acquired a new position in shares of Capricor Therapeutics in the 1st quarter worth approximately $40,000. Vanguard Group Inc. raised its holdings in shares of Capricor Therapeutics by 17.2% in the 1st quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company’s stock worth $9,274,000 after purchasing an additional 200,499 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in Capricor Therapeutics by 12.8% during the second quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock valued at $381,000 after purchasing an additional 9,040 shares during the last quarter. Finally, Rhumbline Advisers bought a new stake in Capricor Therapeutics during the second quarter worth approximately $147,000. Institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.